TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25373361

Group type: EXPERIMENTAL
Intervention: bFGF treatment (0.2-0.25 mL of bFGF solution applied directly onto the TM once daily until closure)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Observation group (spontaneous healing)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: bFGF treatment (subgroup D, applied after 3 days post-injury)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Observation group (subgroup A and B)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: bFGF treatment (subgroup C and D)
Number of subjects: 93
Study: 24933332

Group type: EXPERIMENTAL
Intervention: Ramucirumab plus docetaxel
Number of subjects: 1253

Group type: COMPARATOR
Intervention: Placebo plus docetaxel
Number of subjects: 1253
Study: 19720911

Group type: EXPERIMENTAL
Intervention: BCT with tumor bed radiation boost
Number of subjects: 498

Group type: COMPARATOR
Intervention: BCT without tumor bed radiation boost
Number of subjects: 498
Study: 17449934

Group type: EXPERIMENTAL
Intervention: Nadroparin (7,500 U, twice daily)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Coumarin derivatives with aspirin
Number of subjects: 25
Study: 15200403

Group type: EXPERIMENTAL
Intervention: Online lecture with audio
Number of subjects: 59

Group type: COMPARATOR
Intervention: Online lecture without audio
Number of subjects: 59
Study: 12185892

Group type: EXPERIMENTAL
Intervention: Multiple imputation of CD4 values based on other health status measures and event status
Number of subjects: 1530

Group type: COMPARATOR
Intervention: Baseline CD4
Number of subjects: 1530

Group type: COMPARATOR
Intervention: Last measured CD4 before an event
Number of subjects: 1530

Group type: COMPARATOR
Intervention: Time-dependent covariate based on carrying the last CD4 value forward
Number of subjects: 1530
Study: 9585278

Group type: EXPERIMENTAL
Intervention: Patient-controlled sedation (PCS)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Anesthesiologist-controlled sedation (ACS)
Number of subjects: 11
Study: 7651639

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate therapy
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate therapy with ethinyl E2 supplementation
Number of subjects: 34
Study: 2644372

Group type: EXPERIMENTAL
Intervention: Transparent dressing
Number of subjects: 115

Group type: COMPARATOR
Intervention: Gauze dressing
Number of subjects: 115
Study: 7422423

Group type: EXPERIMENTAL
Intervention: Self-hypnosis only (Group A)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Self-hypnosis with biofeedback (Group B)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Biofeedback only (Group C)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Self-hypnosis (Group A) and Self-hypnosis with biofeedback (Group B)
Number of subjects: 48
Study: 30694972

Group type: EXPERIMENTAL
Intervention: LLRE + BFR (low-load resistance exercise at 20% one-repetition maximum)
Number of subjects: 20

Group type: COMPARATOR
Intervention: REST + BFR
Number of subjects: 20

Group type: COMPARATOR
Intervention: LLRE
Number of subjects: 20
Study: 27916207

Group type: EXPERIMENTAL
Intervention: Insulin-supplemented medium
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control medium
Number of subjects: 360
Study: 26551369

Group type: EXPERIMENTAL
Intervention: Partial carious dentin removal
Number of subjects: 42

Group type: COMPARATOR
Intervention: Healthy dentin
Number of subjects: 42
Study: 23895188

Group type: EXPERIMENTAL
Intervention: Birth Preparation Programme (BPP)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 197
Study: 23192919

Group type: EXPERIMENTAL
Intervention: Admission B-type natriuretic peptide (BNP) levels
Number of subjects: 979

Group type: EXPERIMENTAL
Intervention: Addition of BNP to clinical risk prediction model
Number of subjects: 979

Group type: EXPERIMENTAL
Intervention: Addition of BNP to the Mehran Risk Score
Number of subjects: 979
Study: 19851754

Group type: EXPERIMENTAL
Intervention: Patellar tendon graft
Number of subjects: 68

Group type: COMPARATOR
Intervention: Hamstring graft
Number of subjects: 68
Study: 18818254

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring
Number of subjects: 71

Group type: COMPARATOR
Intervention: Standard antenatal care
Number of subjects: 71
Study: 15947280

Group type: EXPERIMENTAL
Intervention: Montelukast (cysteinyl leukotriene antagonist)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Loratadine (antihistamine)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Exercise challenge
Number of subjects: 25
Study: 11900269

Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg/day for 6 months)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 9951500

Group type: EXPERIMENTAL
Intervention: LASIK
Number of subjects: 26

Group type: COMPARATOR
Intervention: PRK
Number of subjects: 26
Study: 8674923

Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation (EVL)
Number of subjects: 39
Study: 2129822

Group type: EXPERIMENTAL
Intervention: Ispaghula therapy
Number of subjects: 20
Study: 6172332

Group type: EXPERIMENTAL
Intervention: MEVP (methotrexate, cyclophosphamide, vincristine, prednisolone)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: CVPP
Number of subjects: 21
Study: 31130060

Group type: COMPARATOR
Intervention: Corticosteroid injection
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Foot orthoses
Number of subjects: 103
Study: 28390770

Group type: EXPERIMENTAL
Intervention: Intramuscular injections of concentrated bone marrow aspirate (cBMA) via MarrowStim
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 25881966

Group type: EXPERIMENTAL
Intervention: levofloxacin/bismuth therapy
Number of subjects: 284

Group type: COMPARATOR
Intervention: BMT quadruple therapy
Number of subjects: 284
Study: 23528546

Group type: EXPERIMENTAL
Intervention: 0.2% polyhexamethylene biguanide dressing (Group A)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Non-occlusive dressing (Group B)
Number of subjects: 197
Study: 21309658

Group type: EXPERIMENTAL
Intervention: Low Glycemic Load (LGL) meals
Number of subjects: 88

Group type: COMPARATOR
Intervention: High Glycemic Load (HGL) meals
Number of subjects: 88
Study: 19482764

Group type: EXPERIMENTAL
Intervention: Light-protected parenteral nutrition (n = 428)
Number of subjects: 866

Group type: COMPARATOR
Intervention: Light-exposed parenteral nutrition (n = 438)
Number of subjects: 866
Study: 17312289

Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 281

Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 281
Study: 15344424

Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Acupoint Stimulation (TEAS)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control
Number of subjects: 106
Study: 11182041

Group type: EXPERIMENTAL
Intervention: Paclitaxel (135 mg/m2, 3 h) and Carboplatin (AUC 4-5)
Number of subjects: 11
Study: 9391999

Group type: EXPERIMENTAL
Intervention: Oral trimegestone, 0.10 mg/day
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Oral trimegestone, 0.25 mg/day
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Oral trimegestone, 0.50 mg/day
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Oral 17‐beta‐oestradiol, 2 mg/day
Number of subjects: 38
Study: 7948238

Group type: COMPARATOR
Intervention: Conventional spike technique (C)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: O-set technique (O)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: UVXD technique (U)
Number of subjects: 100
Study: 3371480

Group type: EXPERIMENTAL
Intervention: Home insemination
Number of subjects: 53

Group type: COMPARATOR
Intervention: Clinic insemination
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Home insemination (in couples who did not meet criteria)
Number of subjects: 53
Study: 28492428

Group type: EXPERIMENTAL
Intervention: Plain gut suture
Number of subjects: 49

Group type: COMPARATOR
Intervention: PG910 (Vicryl) suture
Number of subjects: 49
Study: 26805433

Group type: EXPERIMENTAL
Intervention: Oral inosine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25611939

Group type: EXPERIMENTAL
Intervention: Playworks
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control
Number of subjects: 29
Study: 22503993

Group type: EXPERIMENTAL
Intervention: Intentional weight loss (WL)
Number of subjects: 3
Study: 20873243

Group type: EXPERIMENTAL
Intervention: Metformin alone (n=46)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Metformin and gliclaside MB (n=47)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Metformin and insulin (n=44)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Insulin (n=45)
Number of subjects: 182
Study: 18954638

Group type: EXPERIMENTAL
Intervention: Right ventricle-pulmonary artery shunt
Number of subjects: 0

Group type: COMPARATOR
Intervention: Modified Blalock-Taussig shunt
Number of subjects: 0
Study: 16351785

Group type: EXPERIMENTAL
Intervention: R-CHOP regimen
Number of subjects: 63

Group type: COMPARATOR
Intervention: CHOP regimen
Number of subjects: 63
Study: 12477585

Group type: COMPARATOR
Intervention: 0.125% bupivacaine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine and ketamine (1 mg/mL)
Number of subjects: 50

Group type: COMPARATOR
Intervention: bupivacaine group
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: bupivacaine-ketamine group
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: bupivacaine-ketamine
Number of subjects: 50
Study: 10361873

Group type: EXPERIMENTAL
Intervention: Danaparoid sodium (750 anti-Xa units once daily for 8 weeks)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 8572838

Group type: EXPERIMENTAL
Intervention: Enalapril maleate, 10 mg/d for 5 years
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo for 5 years
Number of subjects: 94
Study: 1767693

Group type: EXPERIMENTAL
Intervention: Family Practice Clinic Patient Medical Advisor Booklet and an educational presentation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Family Practice Clinic Patient Medical Advisor Booklet
Number of subjects: 0
Study: 7081684

Group type: EXPERIMENTAL
Intervention: Methylprednisolone 30 mg/kg administered following induction of anaesthesia and repeated with the start of cardiopulmonary bypass
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no steroids)
Number of subjects: 0
Study: 31041855

Group type: EXPERIMENTAL
Intervention: Blonanserin (8 to 24 mg/d)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Haloperidol (4 to 12 mg/d)
Number of subjects: 265
Study: 29310989

Group type: EXPERIMENTAL
Intervention: Variability in HDL-cholesterol measurements
Number of subjects: 9572

Group type: EXPERIMENTAL
Intervention: Variability in triglyceride measurements
Number of subjects: 9572

Group type: EXPERIMENTAL
Intervention: Variability in LDL-cholesterol measurements
Number of subjects: 9572

Group type: EXPERIMENTAL
Intervention: Variability in triglyceride and LDL-cholesterol measurements
Number of subjects: 9572

Group type: EXPERIMENTAL
Intervention: Variability in HDL-cholesterol, triglycerides, and LDL-cholesterol
Number of subjects: 9572
Study: 27083200

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Electroacupuncture + Cognitive Behavioural Therapy (EA+CBT)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Untreated Control
Number of subjects: 33
Study: 24803302

Group type: EXPERIMENTAL
Intervention: AMG 181 (210 mg s.c.)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: AMG 181 (various doses: 0.7, 2.1, 7, 21, 70 mg s.c. or i.v., 210 mg s.c. or i.v., 420 mg i.v.)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: AMG 181 (various doses)
Number of subjects: 72
Study: 24712204

Group type: EXPERIMENTAL
Intervention: Cefalotin for 24 hours plus ten additional days of dicloxacillin (Group I)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Cefalotin for 24 hours and placebo for ten days (Group II)
Number of subjects: 131
Study: 19348675

Group type: EXPERIMENTAL
Intervention: Sevoflurane + fentanyl
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Sevoflurane + remifentanil
Number of subjects: 411

Group type: COMPARATOR
Intervention: Propofol + remifentanil
Number of subjects: 411
Study: 16926662

Group type: EXPERIMENTAL
Intervention: Vitamin E (500 IU per day)
Number of subjects: 409

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 409
Study: 14635749

Group type: EXPERIMENTAL
Intervention: Conventional dose (inj. hydrocortisone 100 mg IV 6‐hourly for 3 days)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Intermediate dose (inj. hydrocortisone 100 mg IV 6‐hourly on day 1, 100 mg IV 8‐hourly on day 2, and 100 mg IV 12‐hourly on day 3)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Low dose protocol (inj. hydrocortisone 25 mg IV 6‐hourly on day 1, 25 mg IV 8‐hourly on day 2 and 25 mg IV 12‐hourly on day 3)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Not receiving hydrocortisone (Group II)
Number of subjects: 130
Study: 11304719

Group type: EXPERIMENTAL
Intervention: r-HuEPO with new stabilizer (glycine and Polysorbate 80) at 150 IU/kg sc dose
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: r-HuEPO with new stabilizer (glycine and Polysorbate 80) at 750 IU/kg sc dose
Number of subjects: 24

Group type: COMPARATOR
Intervention: r-HuEPO without new stabilizer (HSA) at 150 IU/kg sc dose
Number of subjects: 24

Group type: COMPARATOR
Intervention: r-HuEPO without new stabilizer (HSA) at 750 IU/kg sc dose
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both formulations (with and without new stabilizer)
Number of subjects: 24
Study: 8852315

Group type: EXPERIMENTAL
Intervention: Patients with muscle pain
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Self-monitoring of perceived muscle tension by patients with muscle pain
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 20
Study: 1468693

Group type: EXPERIMENTAL
Intervention: Cisplatin and cyclophosphamide with or without doxorubicin
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Initial extrapelvic disease
Number of subjects: 349
Study: 6420161

Group type: EXPERIMENTAL
Intervention: Chap‐5 (adriamycin, cis‐dichlorodiammine platinum (II), hexamethylmelamine, cyclophosphamide)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Hexa CAF (methotrexate, 5‐fluorouracil, hexamethylmelamine, cyclophosphamide)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Chap‐5
Number of subjects: 22

Group type: COMPARATOR
Intervention: Hexa CAF
Number of subjects: 22
Study: 31492718

Group type: EXPERIMENTAL
Intervention: Ladostigil 10 mg/d
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 29966612

Group type: EXPERIMENTAL
Intervention: Misoprostol (200 μg, 4 times daily; n = 42)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo (n = 42)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 84
Study: 26721775

Group type: EXPERIMENTAL
Intervention: Length of hospital stay (LOS)
Number of subjects: 1347
Study: 24650820

Group type: EXPERIMENTAL
Intervention: Prescription drug misuse (PDM) of one class
Number of subjects: 2127

Group type: EXPERIMENTAL
Intervention: Prescription drug misuse (PDM) of two classes
Number of subjects: 2127

Group type: EXPERIMENTAL
Intervention: Prescription drug misuse (PDM) of three classes
Number of subjects: 2127

Group type: COMPARATOR
Intervention: No prescription drug misuse (PDM)
Number of subjects: 2127
Study: 22795277

Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 7500

Group type: COMPARATOR
Intervention: Allopurinol
Number of subjects: 7500
Study: 20166864

Group type: EXPERIMENTAL
Intervention: Three early structured telephone interventions (n=81)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Usual care (n=50)
Number of subjects: 131
Study: 17094975

Group type: EXPERIMENTAL
Intervention: Laser-assisted hatching
Number of subjects: 199

Group type: COMPARATOR
Intervention: Control (no assisted hatching)
Number of subjects: 199
Study: 16219020

Group type: EXPERIMENTAL
Intervention: Recombinant leptin (10 mg/morning, 10 mg/evening, or 20 mg/day)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Recombinant leptin
Number of subjects: 284

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study: 11966742

Group type: EXPERIMENTAL
Intervention: GH replacement
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 9927014

Group type: EXPERIMENTAL
Intervention: Exercise at 50% of VO2peak
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Exercise at 70% of VO2peak
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group (C) during 50% and 70% trials
Number of subjects: 6

Group type: COMPARATOR
Intervention: Comparison of N and C
Number of subjects: 6
Study: 7754943

Group type: EXPERIMENTAL
Intervention: Dual-chamber pacing
Number of subjects: 214

Group type: COMPARATOR
Intervention: Ventricular pacing
Number of subjects: 214

Group type: COMPARATOR
Intervention: No pacing therapy
Number of subjects: 214
Study: 1701097

Group type: EXPERIMENTAL
Intervention: 3% dextran 70 (Dx70)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ringer's acetate
Number of subjects: 40
Study: 7428183

Group type: EXPERIMENTAL
Intervention: Domperidone (acute administration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metoclopramide (acute administration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metoclopramide (further treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Domperidone (prolonged administration)
Number of subjects: 0
Study: 31836949

Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg every 8 weeks (first three doses every 4 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30529157

Group type: EXPERIMENTAL
Intervention: Phrenic nerve infiltration with 10 mL of 0.25% bupivacaine
Number of subjects: 90

Group type: COMPARATOR
Intervention: No phrenic nerve infiltration (control)
Number of subjects: 90
Study: 28845577

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 26860018

Group type: EXPERIMENTAL
Intervention: Meloxicam (15 mg) administered orally two hours before surgery
Number of subjects: 70

Group type: COMPARATOR
Intervention: Celecoxib (400 mg) administered orally two hours before surgery
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Comparison between Meloxicam and Celecoxib
Number of subjects: 70
Study: 23001685

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium
Number of subjects: 0

Group type: COMPARATOR
Intervention: No medication (control)
Number of subjects: 0
Study: 21107599

Group type: EXPERIMENTAL
Intervention: Exercise before diving (Ex)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control dive without exercise before (No-Ex)
Number of subjects: 24
Study: 19245735

Group type: EXPERIMENTAL
Intervention: n-3 long-chain PUFA-supplemented dairy products
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 16400707

Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 12616437

Group type: EXPERIMENTAL
Intervention: Stapled hemorrhoidectomy
Number of subjects: 74

Group type: COMPARATOR
Intervention: Open hemorrhoidectomy (Milligan-Morgan technique)
Number of subjects: 74
Study: 10831636

Group type: EXPERIMENTAL
Intervention: Prednisone and cyclophosphamide
Number of subjects: 20

Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 20
Study: 9360754

Group type: EXPERIMENTAL
Intervention: Acid electrolytic water (AEW)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Tap water (placebo)
Number of subjects: 22
Study: 1492847

Group type: EXPERIMENTAL
Intervention: Newly developed effervescent granules (Imbun) containing 500 mg ibuprofen lysine salt (292.6 mg ibuprofen)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Commercially available granules containing 600 mg ibuprofen
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Newly developed effervescent granules (Imbun)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Commercially available granules
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both preparations
Number of subjects: 12
Study: 3884358

Group type: EXPERIMENTAL
Intervention: S-R theophylline preparation given once each night (mean 11.2 mg/kg/day)
Number of subjects: 9

Group type: COMPARATOR
Intervention: S-R aminophylline preparation every 12 h (mean 10.3 mg theophylline/kg/day)
Number of subjects: 9
Study: 30840576

Group type: EXPERIMENTAL
Intervention: Less invasive technique (Group 2)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Standard technique (Group 1)
Number of subjects: 71
Study: 26696365

Group type: EXPERIMENTAL
Intervention: PPI group (lansoprazole 15 mg twice daily for 2 months)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Non-PPI group
Number of subjects: 48
Study: 25058680

Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir (ATV/r) monotherapy
Number of subjects: 103

Group type: COMPARATOR
Intervention: Atazanavir/ritonavir (ATV/r) along with two NRTIs
Number of subjects: 103
Study: 22901923

Group type: EXPERIMENTAL
Intervention: Chloral hydrate (40 mg/kg)
Number of subjects: 100
Study: 20142295

Group type: EXPERIMENTAL
Intervention: 1.5-inch needle
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1-inch needle
Number of subjects: 0
Study: 17908886

Group type: EXPERIMENTAL
Intervention: Immobilization in external rotation for three weeks
Number of subjects: 198

Group type: COMPARATOR
Intervention: Immobilization in internal rotation for three weeks
Number of subjects: 198
Study: 16109088

Group type: EXPERIMENTAL
Intervention: 40 mg alendronate, taken once a week for 6 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 12075559

Group type: EXPERIMENTAL
Intervention: Therapeutic apheresis
Number of subjects: 85
Study: 12363060

Group type: EXPERIMENTAL
Intervention: Chloroquine 50 mg/kg
Number of subjects: 129

Group type: COMPARATOR
Intervention: Chloroquine 25 mg/kg
Number of subjects: 129
Study: 9513587

Group type: EXPERIMENTAL
Intervention: Nebulized furosemide (40 mg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 42